FATE Earnings

Quarterly EPS
$-0.40
Q3 2024
$-0.44
Q4 2024
$-0.32
Q1 2025
$-0.29
Q2 2025
$-0.27
Q3 2025
$-0.27
Q4 2025
$-0.26
Q1 2026
$-0.25
Q2 2026
Latest Revenue2.1M
Latest Net Income-30159000
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026-$0.252.1M-30159000+9.2%+13.8%
Q1 2026-$0.261.3M-31213000-20.3%+18.8%
Q4 2025-$0.271.4M-32374000-26.4%+38.6%
Q3 2025-$0.271.7M-32250000-43.4%+32.5%
Q2 2025-$0.291.9M-34070000-71.8%+12.1%
Q1 2025-$0.321.6M-37621000-15.4%+31.9%
Q4 2024-$0.441.9M-52153000+11.0%+2.2%
Q3 2024-$0.403.1M-47678000+58.1%+13.0%
Q2 2024-$0.336.8M-38427000
Q1 2024-$0.471.9M-48004000
Q4 2023-$0.451.7M-44122000
Q3 2023-$0.461.9M-45170000
Fate Therapeutics (FATE) — Earnings